|
1
|
Ames RS, Sarau HM, Chambers JK, Willette
RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF,
Coatney RW, et al: Human urotensin-II is a potent vasoconstrictor
and agonist for the orphan receptor GPR14. Nature. 401:282–286.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ross B, McKendy K and Giaid A: Role of
urotensin II in health and disease. Am J Physiol Regul Integr Comp
Physiol. 298:R1156–R1172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Iglewski M and Grant SR: Urotensin
II-induced signaling involved in proliferation of vascular smooth
muscle cells. Vasc Health Risk Manag. 6:723–734. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y, Li Y, Wei R, Wang Z, Bu D, Zhao
J, Pang Y and Tang C: Urotensin II is an autocrine/paracrine growth
factor for aortic adventitia of rat. Regul Pept. 151:88–94. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Watanabe T, Suguro T, Kanome T, Sakamoto
Y, Kodate S, Hagiwara T, Hongo S, Hirano T, Adachi M and Miyazaki
A: Human urotensin II accelerates foam cell formation in human
monocyte-derived macrophages. Hypertension. 46:738–744. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsoukas P, Kane E and Giaid A: Potential
clinical implications of the urotensin II receptor antagonists.
Front Pharmacol. 2:382011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Watson AM, Olukman M, Koulis C, Tu Y,
Samijono D, Yuen D, Lee C, Behm DJ, Cooper ME, Jandeleit-Dahm KA,
et al: Urotensin II receptor antagonism confers vasoprotective
effects in diabetes associated atherosclerosis: Studies in humans
and in a mouse model of diabetes. Diabetologia. 56:1155–1165. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hassan GS, Douglas SA, Ohlstein EH and
Giaid A: Expression of urotensin-II in human coronary
atherosclerosis. Peptides. 26:2464–2472. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park SL, Lee BK, Kim YA, Lee BH and Jung
YS: Inhibitory effect of an urotensin II receptor antagonist on
proinflammatory activation induced by urotensin II in human
vascular endothelial cells. Biomol Ther (Seoul). 21:277–283. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Enzerink A and Vaheri A: Fibroblast
activation in vascular inflammation. J Thromb Haemost. 9:619–626.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li AC and Glass CK: The macrophage foam
cell as a target for therapeutic intervention. Nat Med.
8:1235–1242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maiellaro K and Taylor WR: The role of the
adventitia in vascular inflammation. Cardiovasc Res. 75:640–648.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang W, Yang JH, Pan CS, Qi YF, Pang YZ
and Tang CS: Effects of adrenomedullin on cell proliferation in rat
adventitia induced by aldosterone. J Hypertens. 22:1953–1961. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu F, Ji J, Li L, Chen R and Hu W:
Activation of adventitial fibroblasts contributes to the early
development of atherosclerosis: A novel hypothesis that complements
the ‘Response-to-Injury Hypothesis’ and the ‘Inflammation
Hypothesis’. Med Hypotheses. 69:908–912. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stenmark KR, Davie N, Frid M,
Gerasimovskaya E and Das M: Role of the adventitia in pulmonary
vascular remodeling. Physiology (Bethesda). 21:134–145. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sartore S, Chiavegato A, Faggin E, Franch
R, Puato M, Ausoni S and Pauletto P: Contribution of adventitial
fibroblasts to neointima formation and vascular remodeling: From
innocent bystander to active participant. Circ Res. 89:1111–1121.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gilbert KC and Brown NJ: Aldosterone and
inflammation. Curr Opin Endocrinol Diabetes Obes. 17:199–204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xanthakis V and Vasan RS: Aldosterone and
the risk of hypertension. Curr Hypertens Rep. 15:102–107. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang YG, Li J, Li YG and Wei RH:
Urotensin II induces phenotypic differentiation, migration, and
collagen synthesis of adventitial fibroblasts from rat aorta. J
Hypertens. 26:1119–1126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang YG, Hu YC, Mao YY, Wei RH, Bao SL,
Wu LB and Kuang ZJ: Transforming growth factor-β1 involved in
urotensin II-induced phenotypic differentiation of adventitial
fibroblasts from rat aorta. Chin Med J (Engl). 123:3634–3639.
2010.PubMed/NCBI
|
|
21
|
Dong X, Ye X, Song N, Zhao J, Di B, Peng
F, Tang C and Ding W: Urotensin II promotes the production of LTC4
in rat aortic adventitial fibroblasts through NF-κB-5-LO pathway by
p38 MAPK and ERK activations. Heart Vessels. 28:514–523. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelm M: Nitric oxide metabolism and
breakdown. Biochim Biophys Acta. 1411:273–289. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim DK, Huh JE, Lee SH, Hong KP, Park JE,
Seo JD and Lee WR: Angiotensin II stimulates proliferation of
adventitial fibroblasts cultured from rat aortic explants. J Korean
Med Sci. 14:487–496. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tsuruda T, Kato J, Cao YN, Hatakeyama K,
Masuyama H, Imamura T, Kitamura K, Asada Y and Eto T:
Adrenomedullin induces matrix metalloproteinase-2 activity in rat
aortic adventitial fibroblasts. Biochem Biophys Res Commun.
325:80–84. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rajagopalan S, Duquaine D, King S, Pitt B
and Patel P: Mineralocorticoid receptor antagonism in experimental
atherosclerosis. Circulation. 105:2212–2216. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takai S, Jin D, Muramatsu M, Kirimura K,
Sakonjo H and Miyazaki M: Eplerenone inhibits atherosclerosis in
nonhuman primates. Hypertension. 46:1135–1139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii
T, Higaki J and Horiuchi M: Eplerenone with valsartan effectively
reduces atherosclerotic lesion by attenuation of oxidative stress
and inflammation. Arterioscler Thromb Vasc Biol. 26:917–921. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Epstein M: Aldosterone and the
hypertensive kidney: Its emerging role as a mediator of progressive
renal dysfunction: A paradigm shift. J Hypertens. 19:829–842. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ehrhart-Bornstein M, Lamounier-Zepter V,
Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H,
McCann SM, Scherbaum WA and Bornstein SR: Human adipocytes secrete
mineralocorticoid-releasing factors. Proc Natl Acad Sci USA.
100:pp. 14211–14216. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Libby P, Ridker PM and Maseri A:
Inflammation and atherosclerosis. Circulation. 105:1135–1143. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Joffe HV and Adler GK: Effect of
aldosterone and mineralocorticoid receptor blockade on vascular
inflammation. Heart Fail Rev. 10:31–37. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rocha R, Martin-Berger CL, Yang P,
Scherrer R, Delyani J and McMahon E: Selective aldosterone blockade
prevents angiotensin II/salt-induced vascular inflammation in the
rat heart. Endocrinology. 143:4828–4836. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Segain JP, Rolli-Derkinderen M, Gervois N,
Raingeard de la Blétière D, Loirand G and Pacaud P: Urotensin II is
a new chemotactic factor for UT receptor-expressing monocytes. J
Immunol. 179:901–909. 2007. View Article : Google Scholar : PubMed/NCBI
|
